Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Miscellaneous
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456546/
https://www.ncbi.nlm.nih.gov/pubmed/32816781
http://dx.doi.org/10.1136/annrheumdis-2019-216274corr1
_version_ 1783575818177347584
collection PubMed
description
format Online
Article
Text
id pubmed-7456546
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74565462020-09-04 Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis Ann Rheum Dis Miscellaneous BMJ Publishing Group 2020-09 2020-08-14 /pmc/articles/PMC7456546/ /pubmed/32816781 http://dx.doi.org/10.1136/annrheumdis-2019-216274corr1 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Miscellaneous
Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
title Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
title_full Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
title_fullStr Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
title_full_unstemmed Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
title_short Correction: Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis
title_sort correction: initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (ctd-pah) in the modified intention-to-treat population of the ambition study: post hoc analysis
topic Miscellaneous
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456546/
https://www.ncbi.nlm.nih.gov/pubmed/32816781
http://dx.doi.org/10.1136/annrheumdis-2019-216274corr1

Ejemplares similares